Home Add to Favorite Contact Submit  
           29 March, 2024


    
Category:  Press » Health & Fitness

 

Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel

Popularity:
         Views: 1586
2008-09-03 01:29:05     
Eli Lilly and Company

A sub-analysis of the TRITON-TIMI 38 clinical trial showed that treatment with prasugrel compared with clopidogrel significantly reduced the risk of new or recurrent heart attacks (7.4 percent vs. 9.7 percent, p<0.0001), regardless of whether the events occurred around the time of an artery-opening procedure known as percutaneous coronary intervention (PCI), or if they occurred spontaneously during the longer-term maintenance phase. The analysis was presented today at the European Society of Cardiology (ESC) in Munich, Germany.

The sub-analysis assessed the effect of prasugrel on new or recurrent heart attacks, occurring in the acute setting and during long-term medical treatment (up to 15 months) in 13,608 acute coronary syndromes (ACS) patients who were managed with PCI. New or recurrent heart attacks were classified according to the ESC Universal Definition of Myocardial Infarction as spontaneous (Type 1) or procedure-related (Type 4 or 5).(1) The analysis showed that prasugrel consistently and significantly reduced spontaneous (Type 1) heart attacks by 29 percent compared with clopidogrel (2.5 percent vs. 3.4 percent, p=0.0015) and procedure-related recurrent heart attacks (Type 4 or 5) 24 percent in prasugrel-treated patients compared with those taking clopidogrel (4.9 percent vs. 6.4 percent, p=0.0002).

Long-term treatment with prasugrel, continuing after 30 days for up to 15 months, significantly reduced the risk for patients who suffer any form of heart attack by 23 percent compared with clopidogrel (2.9 percent vs. 3.7 percent, p=0.01). In the sub-analysis, prasugrel was also shown to reduce the risk of a future severe heart attack (ST elevation myocardial infarction (STEMI), a more severe form of ACS with a higher risk of death) by more than 50 percent compared with clopidogrel (p=0.0001).

The main TRITON-TIMI 38 clinical trial, for which overall results were previously published in the New England Journal of Medicine in November 2007 (Vol. 357 No.20), compared prasugrel with clopidogrel (Plavix(R)/Iscover(R)) in patients with ACS undergoing PCI. In the primary analysis of the trial, prasugrel reduced the risk of the composite of cardiovascular death, heart attack or stroke by 19 percent, with an increased risk of major bleeding compared with clopidogrel (2.4 percent vs. 1.8 percent).(2)

Heart attacks are a major manifestation of coronary heart disease, a global health problem. About 7.2 million people die each year from coronary heart disease worldwide.(3) In the United States, the annual rate of heart attack is 920,000, with 600,000 being first-time attacks and 320,000 repeat attacks.(4)

"In this new sub-analysis of TRITON-TIMI 38, we found that the reduction of heart attacks seen with prasugrel compared with clopidogrel was consistent across the spectrum of heart attacks based on type, timing and magnitude," said David Morrow, M.D., M.P.H., associate professor of medicine at Harvard Medical School and the Brigham and Women's Hospital, Boston, USA, and investigator with the Thrombolysis in Myocardial Infarction (TIMI) Study Group.

About TRITON-TIMI 38

TRITON-TIMI 38 was a Phase III, randomized, double-blind, head-to-head clinical trial comparing the effects of prasugrel versus clopidogrel in patients with ACS who were managed with PCI, a procedure to open blockages in heart arteries including the use of coronary stenting. The study enrolled 13,608 patients at 707 trial sites in 30 countries.

The primary endpoint of the study was to compare the effects of prasugrel to clopidogrel on the combined incidence of cardiovascular death, non-fatal heart attack and non-fatal stroke during a median period of at least 12 months following PCI. Patients were randomly assigned to one of two treatment groups and given a loading dose of either prasugrel 60 mg or the approved loading dose of clopidogrel 300 mg anytime between randomization and one hour after the completion of the PCI procedure, followed by a daily maintenance dose of either prasugrel 10 mg or clopidogrel 75 mg. All patients also received a daily low dose of aspirin.

About Acute Coronary Syndromes

Acute coronary syndromes, which is comprised of heart attacks and unstable angina (chest pain), affects more than 1.4 million people in the United States annually.(5) ACS, a fatal consequence of coronary heart disease, is the single most common cause of death in the European Union, accounting for more than 741,000 deaths in the EU each year.(6) Heart attack is a major manifestation of coronary heart disease, which occurs when the arteries become narrowed or clogged by cholesterol and fat deposits and cannot supply enough blood to the heart. In some cases, a blood clot may partially or totally block the blood supply to the heart resulting in ACS.(7) Many ACS patients are managed with PCI, which usually includes a stent placement.

About prasugrel

Daiichi Sankyo Company, Limited (TSE: 4568), and Eli Lilly and Company (NYSE: LLY) are co-developing prasugrel, an investigational oral antiplatelet agent invented by Daiichi Sankyo and its Japanese research partner Ube Industries, Ltd., as a potential treatment, initially for patients with acute coronary syndromes undergoing PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in clogged arteries and may lead to heart attack or stroke.

About Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the merger of two leading century-old Japanese pharmaceutical companies, is a global pharmaceutical innovator, continuously generating innovative drugs that enrich the quality of life for patients around the world. The company uses its cumulative knowledge and expertise in the fields of cardiovascular disease, cancer, metabolic disorders, and infection as a foundation for developing an abundant product lineup and R&D pipeline.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.

This press release contains certain forward-looking statements about the potential of the investigational compound prasugrel (CS-747, LY640315) and reflects Daiichi Sankyo's and Lilly's current beliefs. However, as with any pharmaceutical compound under development, there are substantial risks and uncertainties in the process of development and regulatory review. There is no guarantee that the compound will receive regulatory approval, that the regulatory approval will be for the indication(s) anticipated by the companies, or that later studies and patient experience will be consistent with study findings to date. There is also no guarantee that the compound will prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filing with the United States Securities and Exchange Commission and Daiichi Sankyo's filings with the Tokyo Stock Exchange. Daiichi Sankyo and Lilly undertake no duty to update forward-looking statements.

Plavix(R)/Iscover(R) are registered trademarks of sanofi-aventis.

P-LLY

1. Type 1: Spontaneous myocardial infarction related to ischemia due to a primary coronary event

Type 2: Myocardial infarction secondary to ischemia due to either increased oxygen demand of the heart or decreased blood supply

Type 4/Type 5: Myocardial infarction associated with PCI/CABG

Thygesen K et al. Universal Definition of Myocardial Infarction. EHJ(2007);28:2525-2538 http://www.escardio.org/guidelines-surveys/esc- guidelines/GuidelinesDocuments/guidelines-universal-MI-FT.pdf. Accessed August 13, 2008.

2. Wiviott, S, Braunwald, E, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine. November 2007;357:2001-15.

3. World Health Organization. The Atlas of Heart Disease and Stroke - Deaths from Coronary Heart Disease. http://www.who.int/cardiovascular_diseases/en/cvd_atlas_14_deathHD.pdf. Accessed August 13, 2008.

4 .American Heart Association. Heart Disease and Stroke Statistics - 2008 Update. http://www.americanheart.org/downloadable/heart/1200082005246HS_Stats%20200 8.f inal.pdf. Accessed August 13, 2008.

5 .American Heart Association. Heart Disease and Stroke Statistics - 2008 Update. http://www.americanheart.org/downloadable/heart/1200082005246HS_Stats%20200 8.f inal.pdf. Accessed August 13, 2008.

6. British Heart Foundation Health Promotion Research Group. European Cardiovascular Disease Statistics 2008, http://www.ehnheart.org/files/statistics%202008%20web-161229A.pdf, Accessed August 13, 2008.

7. WebMD Medical Reference in Collaboration with the Cleveland Clinic. Heart Disease: Coronary Artery Disease. http://www.webmd.com/heart- disease/guide/heart-disease-coronary-artery-disease. Accessed August 13, 2008.

Specialized in: Prasugrel Significantly - Recurrent Heart Attacks - Both Acute - Pci - Clopidogrel
URL: http://www.escardio.org
Print press release      Bookmark this page
Related Press releases 
Innovative Menopause Support Now Available in Hampton (Popularity: ): Hampton, UK - Menopause is a natural transition in a woman's life, yet it often comes with challenges that can affect daily life. Recognizing the need for supportive and effective solutions, a new initiative focusing on peri menopause treatment and menopause help in the UK has been launched. This groundbreaking service is available through Let's All Talk Menopause, an organization dedicated to providing comprehensive support and treatment options for women ...
ehnote Ushers in a New Era of Ophthalmology Practice Management with Groundbreaking EMR Software (Popularity: ): ehnote, a pioneer in ophthalmology-specific electronic medical record (EMR) software, unveils the latest advancements to its comprehensive solution, empowering eye care professionals to streamline operations, elevate patient care, and achieve unprecedented levels of efficiency.ehnote’s innovative EMR software is meticulously crafted to address the unique challenges faced by ophthalmology practices. Its robust suite of features empowers practitioners to optimize patient flow, enhance clinical decision-making, and simplify administrative tasks with unparalleled ease. ...
NC Physicians Release Article Detailing Health Exercise Regime Tips For 2023 (Popularity: ): Durham, NC (press.abc-directory ) May 10, 2023 - Imperial Center Family Medicine, a NC Primary Care Physician Practice, has recently released a new blog that discusses some health exercise regime tips for 2023. This new article was designed in order to help people learn how to take care of their physical and mental well-being so they know when they need to seek professional help for their symptoms. At Imperial Center ...
Raleigh Gynecologists Release Article Providing Tips For Managing Birth Control Pill Contraception (Popularity: ): Raleigh, North Carolina (press.abc-directory ) March 14, 2023 - The Raleigh Gynecologists at Raleigh Gynecology recently released a new informational resource that provides tips for women looking to learn more about managing birth control and contraception methods. The new section can be found on the company's website. The expert gynecologists have designed this article so that it can be used as a research tool and consumer resource for women who ...
Dental Marketer is Happy to Announce the Hiring of an Additional Copywriter (Popularity: ): A proficient and highly known oral healthcare, Dental Marketer is happy to announce a copywriter's hiring. Dentists face difficult challenges, and it is highly imperative to balance the training and services with the running business.Stoney Creek, ON - Canada - June 17th, 2021 -- Dental Marketer hires an additional copywriter to promote their services across a large number of patients, try various advertising models and strategies, and utilize effective marketing ...


Related Business 
Clopidogrel Bisulfate Online (Popularity: ): Clopidogrel Bisulfate is an effective treatment for preventing blood clots in the body. It helps to keep the blood running normally to the heart, brain and additional organs. It is the chemical name for some very famous medicines.
HeartIQ - Heartmath Training UK (Popularity: ): HeartIQ or Heart Intelligence is a term used to describe the innate capacity of the heart to guide, inform and inspire us. Neuroscientists have found that the heart has it’s own independent nervous system leading to the term the ‘mini brain’. There are are at least forty thousand neurons in the heart – as many as are found in various subcortical centres in the brain.
Heart Fit Clinic: Reverse Heart Disease (Popularity: ): Cardiac rehabilitation program to prevent heart attacks and reverse heart disease. Heart stent, heart bypass surgery and heart disease treatment center. To reverse arteria illness you need to learn what to eat, the way to exercise safely and effectively, and management all of your modifiable risk factors to some extent wherever you'll then halt or maybe reverse the illness method. With our on-line programs you may learn everything you would ...
Recurrent Miscarriages (Popularity: ): Recurrent miscarriage is an emotionally difficult problem for patients and a treatment challenge for the physician caring for these individuals. Less than 50 % of patients with recurrent miscarriages will have a defined cause for this problem after appropriate medical evaluation.
Primacor ( Milrinone Lactate Injection ) (Popularity: ): A phosphodiesterase inhibitor (PDE III) that is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. Site provides information for health care professionals and patients.
Select Medical Corporation (Popularity: ): Developing a national network of specialized, acute healthcare facilities and services including long term acute care hospitals, inpatient and outpatient rehabilitation, and contract therapy services.
DDoS Protection & DDoS Mitigation Service (Popularity: ): Servers or networks are made unavailable to customers or users through DDoS attacks which require viable anti- DDoS strategies. These techniques or strategies can be rolled out against volume based attacks, protocol attacks and application layer attacks. Firewall, software solutions, hardware solutions, hosting and cloud-based systems are effective against major and minor attacks.
Gendron (Popularity: ): Manufactures wheelchairs designed specifically for the primary care, sub-acute care, acute care, long term care and home care markets.
FL EXXi Van Service (Popularity: ): FLEXXiVan has been designed to provide hire vehicles to private individuals and businesses on a short-term or medium-term basis. We offer short-term 3 to 24 months flexible van leasing. We can even cater for longer term contract hire for people wanting up to 36 month leases. All of the vehicles on our short-term fleet are under 12 months old and all medium and long term vehicles are brand new. Our ...
SigmaPi Neurosimulator (Popularity: ): SigmaPi is a simulator for recurrent neural neural networks. It uses the LSTM (Long Short-Term Memory) model. It runs on Unix/X11.